Next generation metronomic chemotherapy-report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F16%3A00065793" target="_blank" >RIV/00159816:_____/16:00065793 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/16:00092090 RIV/65269705:_____/16:00065793 RIV/00209805:_____/16:00077923

Result on the web

<a href="http://ecancer.org/journal/10/full/689-next-generation-metronomic-chemotherapy-report-from-the-fifth-biennial-international-metronomic-and-anti-angiogenic-therapy-meeting-6-8-may-2016-mumbai.php" target="_blank" >http://ecancer.org/journal/10/full/689-next-generation-metronomic-chemotherapy-report-from-the-fifth-biennial-international-metronomic-and-anti-angiogenic-therapy-meeting-6-8-may-2016-mumbai.php</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3332/ecancer.2016.689" target="_blank" >10.3332/ecancer.2016.689</a>

Result language

angličtina

Original language name

Next generation metronomic chemotherapy-report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai

Original language description

The 5th Biennial Metronomic and Anti-angiogenic Therapy Meeting was held on 6th - 8th May in the Indian city of Mumbai. The meeting brought together a wide range of clinicians and researchers interested in metronomic chemotherapy, anti-angiogenics, drug repurposing and combinations thereof. Clinical experiences, including many from India, were reported and discussed in three symposia covering breast cancer, head and neck cancers and paediatrics. On the pre-clinical side research into putative mechanisms of action, and the interactions between low dose metronomic chemotherapy and angiogenesis and immune responses, were discussed in a number of presentations. Drug repurposing was discussed both in terms of clinical results, particularly with respect to angiosarcoma and high-risk neuroblastoma, and in pre-clinical settings, particularly the potential for peri-operative interventions. However, it was clear that there remain a number of key areas of challenge, particularly in terms of definitions, perceptions in the wider oncological community, mechanisms of action and predictive biomarkers. While the potential for metronomics and drug repurposing in low and middle income countries remains a key theme, it is clear that there is also considerable potential for clinically relevant improvements in patient outcomes even in high income economies.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2016

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Ecancermedicalscience

ISSN

1754-6605

e-ISSN

—

Volume of the periodical

10

Issue of the periodical within the volume

NOV

Country of publishing house

GB - UNITED KINGDOM

Number of pages

19

Pages from-to

689

UT code for WoS article

000386723100001

EID of the result in the Scopus database

—